drugset / Trial / NCT04112446
Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects
NaSingle-groupOpen-labelBasic science
Summary
This will be a Phase I, open-label, nonrandomized, single-dose study in healthy male subjects.
Timeline
- Start
- 2019-09-20
- Primary completion
- 2019-10-29
- Completion
- 2019-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saroglitazar | Small molecule | 4 mg | Oral |
Indications
No indication recorded.